TY - JOUR
T1 - Characterization of heart failure patients with mid-range left ventricular ejection fraction—a report from the CHART-2 Study
AU - on behalf of the CHART-2 Investigators
AU - Tsuji, Kanako
AU - Sakata, Yasuhiko
AU - Nochioka, Kotaro
AU - Miura, Masanobu
AU - Yamauchi, Takeshi
AU - Onose, Takeo
AU - Abe, Ruri
AU - Oikawa, Takuya
AU - Kasahara, Shintaro
AU - Sato, Masayuki
AU - Shiroto, Takashi
AU - Takahashi, Jun
AU - Miyata, Satoshi
AU - Shimokawa, Hiroaki
N1 - Funding Information:
This study was supported in part by Grants-in Aid from the Ministry of Health, Labour, and Welfare, the Ministry of Education, Culture, Sports, Science, and Technology (H.S. and Y.S.), and the Agency for Medical Research and Development (H.S.). Conflict of interest: The Department of Evidence-based Cardiovascular Medicine, Tohoku University Graduate School of Medicine, is supported in part by unrestricted research grants from Daiichi Sankyo Co., Ltd. (Tokyo, Japan), Bayer Yakuhin, Ltd (Osaka, Japan), Kyowa Hakko Kirin Co., Ltd (Tokyo, Japan), Kowa Pharmaceutical Co., Ltd (Tokyo, Japan), Novartis Pharma K.K. (Tokyo, Japan), Dainippon Sumitomo Pharma, Co., Ltd (Osaka, Japan), and Nippon Boehringer Ingelheim Co., Ltd (Tokyo, Japan). H.S. has received lecture fees from Bayer Yakuhin, Ltd, (Osaka, Japan), Dai-ichi Sankyo Co., Ltd. (Tokyo, Japan) and Novartis Pharma K.K. (Tokyo, Japan).
Funding Information:
This study was supported in part by Grants-in Aid from the Ministry of Health, Labour, and Welfare, the Ministry of Education, Culture, Sports, Science, and Technology (H.S. and Y.S.), and the Agency for Medical Research and Development (H.S.). Conflict of interest: The Department of Evidence-based Cardiovascular Medicine, Tohoku University Graduate School of Medicine, is supported in part by unrestricted research grants from Daiichi Sankyo Co., Ltd. (Tokyo, Japan), Bayer Yakuhin, Ltd (Osaka, Japan), Kyowa Hakko Kirin Co., Ltd (Tokyo, Japan), Kowa Pharmaceutical Co., Ltd (Tokyo, Japan), Novartis Pharma K.K. (Tokyo, Japan), Dainippon Sumitomo Pharma, Co., Ltd (Osaka, Japan), and Nippon Boehringer Ingelheim Co., Ltd (Tokyo, Japan). H.S. has received lecture fees from Bayer Yakuhin, Ltd, (Osaka, Japan), Daiichi Sankyo Co., Ltd. (Tokyo, Japan) and Novartis Pharma K.K. (Tokyo, Japan). The authors thank all members of the Tohoku Heart Failure Association and staff of the Department of Evidence-based Cardiovascular Medicine for their kind contributions (see the Supplementary material online, Appendix S1). This study was supported in part by Grants-in Aid from the Ministry of Health, Labour, and Welfare, the Ministry of Education, Culture, Sports, Science, and Technology (H.S. and Y.S.), and the Agency for Medical Research and Development (H.S.). Conflict of interest: The Department of Evidence-based Cardiovascular Medicine, Tohoku University Graduate School of Medicine, is supported in part by unrestricted research grants from Daiichi Sankyo Co., Ltd. (Tokyo, Japan), Bayer Yakuhin, Ltd (Osaka, Japan), Kyowa Hakko Kirin Co., Ltd (Tokyo, Japan), Kowa Pharmaceutical Co., Ltd (Tokyo, Japan), Novartis Pharma K.K. (Tokyo, Japan), Dainippon Sumitomo Pharma, Co., Ltd (Osaka, Japan), and Nippon Boehringer Ingelheim Co., Ltd (Tokyo, Japan). H.S. has received lecture fees from Bayer Yakuhin, Ltd, (Osaka, Japan), Daiichi Sankyo Co., Ltd. (Tokyo, Japan) and Novartis Pharma K.K. (Tokyo, Japan).
Publisher Copyright:
© 2017 The Authors. European Journal of Heart Failure © 2017 European Society of Cardiology
PY - 2017/10
Y1 - 2017/10
N2 - Background: The new category of heart failure (HF), HF with mid-range left ventricular ejection fraction (LVEF) (HFmrEF), has recently been proposed. However, the clinical features of HFmrEF, with reference to HF with preserved LVEF (HFpEF) and HF with reduced LVEF (HFrEF) in the same HF cohort, remain to be fully examined. Methods and results: In the Chronic Heart Failure Analysis and Registry in the Tohoku District-2 Study, we examined 3480 consecutive HF patients with echocardiography data consisting of 2154 HFpEF (LVEF ≥50%), 596 HFmrEF (LVEF 40–49%) and 730 HFrEF (LVEF <40%). While clinical characteristics and prognostic factors of HFmrEF were intermediate between HFpEF and HFrEF, prognosis of HFmrEF resembled HFpEF and the prognostic impact of cardiovascular medications in HFmrEF resembled that of HFrEF. Analysis of LVEF transition among the three groups revealed that HFmrEF and HFrEF dynamically transitioned to other categories, especially within 1 year, whereas HFpEF did not; HFmrEF at registration transitioned to HFpEF and HFrEF by 44% and 16% at 1 year, and 45% and 21% at 3 years, respectively. Landmark analysis demonstrated that, regardless of HF stages at registration, HFmrEF patients at 1 year had mortality comparable to that of HFpEF patients, which was better than HFrEF patients, but HFmrEF patients at registration had increased mortality when transitioned to HFrEF at 1 year. Conclusions: These results indicate that clinical characteristics of HFmrEF are intermediate between HFpEF and HFrEF and that HFmrEF dynamically transitions to HFpEF or HFrEF, especially within 1 year, suggesting that HFmrEF represents a transitional status or an overlap zone between HFpEF and HFrEF, rather than an independent entity of HF.
AB - Background: The new category of heart failure (HF), HF with mid-range left ventricular ejection fraction (LVEF) (HFmrEF), has recently been proposed. However, the clinical features of HFmrEF, with reference to HF with preserved LVEF (HFpEF) and HF with reduced LVEF (HFrEF) in the same HF cohort, remain to be fully examined. Methods and results: In the Chronic Heart Failure Analysis and Registry in the Tohoku District-2 Study, we examined 3480 consecutive HF patients with echocardiography data consisting of 2154 HFpEF (LVEF ≥50%), 596 HFmrEF (LVEF 40–49%) and 730 HFrEF (LVEF <40%). While clinical characteristics and prognostic factors of HFmrEF were intermediate between HFpEF and HFrEF, prognosis of HFmrEF resembled HFpEF and the prognostic impact of cardiovascular medications in HFmrEF resembled that of HFrEF. Analysis of LVEF transition among the three groups revealed that HFmrEF and HFrEF dynamically transitioned to other categories, especially within 1 year, whereas HFpEF did not; HFmrEF at registration transitioned to HFpEF and HFrEF by 44% and 16% at 1 year, and 45% and 21% at 3 years, respectively. Landmark analysis demonstrated that, regardless of HF stages at registration, HFmrEF patients at 1 year had mortality comparable to that of HFpEF patients, which was better than HFrEF patients, but HFmrEF patients at registration had increased mortality when transitioned to HFrEF at 1 year. Conclusions: These results indicate that clinical characteristics of HFmrEF are intermediate between HFpEF and HFrEF and that HFmrEF dynamically transitions to HFpEF or HFrEF, especially within 1 year, suggesting that HFmrEF represents a transitional status or an overlap zone between HFpEF and HFrEF, rather than an independent entity of HF.
KW - Heart failure
KW - Left ventricular ejection fraction
KW - Prognosis
UR - http://www.scopus.com/inward/record.url?scp=85017364572&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85017364572&partnerID=8YFLogxK
U2 - 10.1002/ejhf.807
DO - 10.1002/ejhf.807
M3 - Article
C2 - 28370829
AN - SCOPUS:85017364572
SN - 1388-9842
VL - 19
SP - 1258
EP - 1269
JO - European Journal of Heart Failure
JF - European Journal of Heart Failure
IS - 10
ER -